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Abstract
Background: Recurrent Aphthous stomatitis (RAS) is a prevalent ulcerative and painful disorder of the oral cavity
with unknown etiology and for which no efficient treatment is currently available.
The present study aimed to evaluate the safety and the efficacy of AphtoFix®, a new mouth ulcer cream that was
developed to help treat RAS. Prior to launching the product on the market, two initial safety assessment studies
were performed.
Subjects and methods: In a first study, the in vitro biocompatibility of AphtoFix® was evaluated on reconstructed
human gingival tissue models according to ISO guidelines 10993. In a second study, the tolerability of AphtoFix®
was evaluated in 20 subjects during a 4-weeks daily application in the mouth. The third study investigated both the
safety and efficacy of AphtoFix® treatment on 19 patients suffering from RAS. This study was done in compliance
with the Helsinki Declaration.
Results: The results of in vitro biocompatibility study showed that AphtoFix® mouth ulcer cream did not induce
any detectable cytotoxicity and irritation. These observations were confirmed in the 4 weeks tolerability study
where no undesired of adverse reactions were noticed. The results of the post-market clinical efficacy study
demonstrated a clear reduction in ulcer size from baseline after 3 days treatment (p < 0.05). Pain intensity reduction
was also observed in all subjects.
Conclusion: The application of AphtoFix® did not induce any undesired skin or mucosa reactions. These initial
findings demonstrate that AphtoFix® is safe and efficient in reducing ulcer size and decreasing the pain intensity
induced by ulcers.
Trial registration: Clinical trial Registry India Nr. CTRI201408004918, Date of registration: 22/08/2014
Keywords: Aphthous stomatitis, Aphthous ulcer, Canker sores, Healing
Introduction
Recurrent aphthous stomatitis (RAS) is a widespread ul-
cerative disease of the oral mucosa characterized by a
painful round, shallow ulcers with well-defined ery-
thematous margin and yellowish-gray pseudomembran-
ous center [1]. RAS affects 5–25 % of the population
and more frequent in patients between 10–40 years of
age [2–9]. This type of ulcer affects women and individ-
uals of higher socioeconomic levels [2, 10, 11].
RAS is classified as minor, major, and herpetiform.
Seventy to 87 % of all RAS cases are minor [12, 13].
After 24 to 48 h preceding the development of a minor
aphthous ulcer, subjects may experience a pricking or
burning sensation in the mucosa. Typically, the ulcers
are less than 1 cm in diameter and less than five occur
at any one time. These ulcers are self-limiting and re-
solve within 7–10 days without scarring [1, 12, 14–16].
Major aphthae are larger and cause deeper ulcers.
They usually take more than a month to heal, and fre-
quently leave a scar. These typically develop after
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puberty with frequent recurrences. Herpetiform ulcera-
tions are the most severe form. It is characterized by
small, numerous, 1 to 3 mm lesions that form clusters.
They typically heal in less than a month without
scarring [17].
RAS is a difficult disorder to treat. All therapies are
aimed to decrease the painful symptoms and duration of
the ulcers [18, 19]. Pain is subjective and depends on
several factors such as personal experience, age, social,
ethnic factors, and perceptual abilities [20], and patients
may seek advice from a variety of sources as regards ap-
propriate therapy and often self- medicate with a range
of agents [21]. Actually, topical or systemic antibacterial
such us chlorhexidine, anti-inflammatory, immunomod-
ulatory, or symptomatic treatments are used however
such treatments are not totally reliable [12, 19, 22–26].
The inflammatory process plays an important role in
RAS. Neutrophils and mononuclear cell infiltration in the
lamina propria determine the primary histologic charac-
teristics [1, 27]. Local immune dysfunction exerts also a
significant role in the development of RAS [28, 29]. The
presence of abnormal oral flora was associated with an ab-
errant immune and inflammation response that is why
oral bacteria play a primary pathogenic role in the devel-
opment of RAS. Due to the potential multifactorial eti-
ology and pathophysiology, the optimal therapeutic agent
should ideally combine several bioactive agents [28, 30].
Several topical agents are available for symptomatic re-
lief such as antibiotics, local anaesthetics, antihistamines,
non-steroidal anti-inflammatory drugs, enzymatic prepa-
rations, gammaglobulins and immunosuppressants. How-
ever, the problem lies that the efficacy of the majority of
these agents has not been adequately evaluated in de-
signed and controlled clinical trials [12, 15, 29, 31–34].
AphtoFix® mouth ulcer cream is a new generation of
mouth ulcer cream with protective as well as adhesive
properties that enhance the healing of the ulcer. The ad-
hesive properties of AphtoFix® are derived from the
Cellulose Gum and Calcium/Sodium PVM/MA Copoly-
mer, which modify the cream’s physical properties on
contact with moisture to create a thin, elastic cushion
against pressure sores. AphtoFix® mouth ulcer cream
contains ingredients that activate on contact with the
mouths saliva. This enables the cream to create a pro-
tective and lasting layer over the ulcer area.
The aim of this study is to evaluate the safety and effi-
cacy of AphtoFix in the management of RAS. The safety
of AphtoFix® was assessed firstly by testing the cytotox-
icity and irritation on in vitro reconstructed human gin-
gival tissue according to ISO10993 and secondly by
applying this product on 20 healthy subjects during
4 weeks.
The clinical efficacy of AphtoFix® was studied on 19
subjects suffering from RAS. The majority of subjects
have recurrent aphthous ulceration which tend to be
otherwise healthy without signs of systemic disease
(minor ulcer). Ulcer parameters such as size, pain inten-
sity and duration of each ulcer are evaluated in this
study.
Methods
In vitro biocompatibility evaluation according to
ISO10993-part1
Materials
Used Materials: Reconstructed human gingival epithelial
tissues
In this study we used the three dimensional recon-
structed human gingival epithelium model (Sterlab,
France, batch number 1301 GEN 01) that consists of
normal human gingival keratinocytes that were cultured
for 5 days on 0.5 cm2 polycarbonate filter inserts at the
air-liquid interface. The Sterlab gingival model presents
a histological morphology comparable to the in vivo hu-
man tissue. After 5 days of tissue reconstruction, the
gingival tissues were transferred on an agarose gel and
incubated at room temperature during 24 h (simulation
of shipping conditions). Inserts were removed from the
agarose gel and transferred on 1 mL growth medium.
Then tissues were placed at 36.5 °C / 5 % CO2 for 24 h.
Method of analysis
 Cytotoxicity assay (according to ISO10993-05 for
gingival epithelium)
Each test substance (AphtoFix®, negative and
positive controls) was topically applied on two
reconstructed human gingival tissues for 24 h at
36.5 °C / 5 % CO2. After exposure, all tissues were
rinsed with Phosphate Buffer Saline. Then, cell
viability was determined by incubating the tissues for
three hours with 300 μL MTT solution (0.5 mg/mL).
After MTT incubation, tissues were rinsed 3 times
with PBS and consequently extracted with 1 ml of
Isopropanol. Optical density was quantified by
spectrophotometry at 550 nm wavelength.
Quantitative viability was determined as a percentage
of negative control.
 Irritation assay (according to ISO10993-10 for
gingival epithelium)
Each test substance (AphtoFix®, negative and
positive controls) were topically applied on two
reconstructed gingival tissues for 2 h followed by a
42 h recovery incubation at 36.5 °C / 5 % CO2.
After exposure, tissues were rinsed with Phosphate
Buffer Saline. Then, cell viability was determined by
incubating the tissues for three hours with 300 μL
MTT solution (0.5 mg/mL). Optical density was
quantified by spectrophotometry at 550 nm
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wavelength. Quantitative viability was determined as
a percentage of negative control.
In vivo safety evaluation
An in vivo clinical trial was conducted on 20 healthy
subjects to evaluate the safety of AphtoFix® application
during 4 weeks. The study population included 6 males
and 14 females. The mean age of this group is
38.45 years. The aim of this study was to examine the
tolerability of AphtoFix® mouth ulcer cream according
to clinical-dermatological test criteria. Before the com-
mencement of this trial, all participants were examined
for eventual skin irritation by 2 specialists in dermatol-
ogy and Venerology from Dermatest® GmbH Research
Institute. Only subjects without any pathological skin
disorders were included in the test group. The partici-
pants were able to consult the physicians in charge of
the trail any day in case of any objective or subjective
skin changes were noted.
The test participants were instructed to use the prod-
uct in the mouth (topical application on the oral mu-
cosa) 2 to 4 times per day during 4 weeks. A small
amount of cream was applied on lips, cheek, tongue and
jaw. In addition, the participants were also advised to
not to use any other skin care product in the test area
during the course of the 4 weeks test period.
In vivo efficacy and safety evaluation of AphtoFix®
Study population
The study was performed at the Poojan Multispeciality
Hospital and the APL Institute of clinical Laboratory &
Research (Ahmedabad-380052, Gujarat, India). 22 sub-
jects were screened and enrolled into the study accord-
ing to inclusion and exclusion criteria.
Inclusion criteria:
(1) Male or female subjects with 18 – 65 years of age;
(2) mouth ulcer size >2 mm at easily accessible location
in the mouth allowing easy evaluation and treatment; (3)
Subject with start of mouth ulceration within 48 h; (4)
Subject who agreed not to use any other medication to
treat mouth ulcer during study period; (5) Subject will-
ing to comply with the study schedule and procedures;
(6) Subject or legally acceptable representative (LAR) of
subject willing to sign and date written informed con-
sent to participate in the study. However, if the subject/
LAR of subject would be illiterate, the impartial witness
would sign the Informed Consent Form (ICF).
Exclusion criteria:
(1) Subjects with a history of allergy for ingredients
present in AphtoFix®®; (2) Subjects with any invasive
dental procedures within 2 weeks prior to screening
visit; (3) History of uncontrolled chronic disease (e.g.
chronic liver disease, chronic renal disease); (4) Use of
any other medication to treat mouth ulcer in current
episode; (5) Participation in any other clinical study dur-
ing last 30 days; (6) Subject with any condition which in
the opinion of the investigator makes the subject unsuit-
able for inclusion; (7) Subject is a female who is preg-
nant or willing to get pregnant, not ready to use
contraceptive measures during the trial period, or is
breast feeding.
Out of 22 enrolled subjects, 19 subjects were analyzed
and 3 subjects were excluded from the analysis since
they were lost during follow up and hence not consid-
ered for statistical analysis.
Ethical approval and informed consent
The present research conformed to the Helsinki Declar-
ation, and ethical clearance and approval letter was ob-
tained from Sangini Hospital Ethics Committee in India
issued by the Department of Health and Human Service
(DHHS-IORG0007258), Office of Human Research Protec-
tion (OHRP-IRB00008709) and Drug Controller General of
India (DCGI-ECR/147/Inst/Gj/2013).
All participants received a full explanation of the study
and provided written informed consent. Information
provided to the subjects was pre-approved by IEC
(Indian Ethical committee).
The subjects were informed about the purpose, proce-
dures to be carried out, potential hazards and the sub-
ject's right to claim compensation in case of trial related
injury and death before participating in the study. The
written informed consent form and patient information
sheet included all the information required to fulfil the
ICH-GCP guidelines and recommendations published by
Government of India.
Subjects were allowed to ask questions and clarify
their doubts regarding any aspect of the study. Signing
the informed consent form meant that the subjects con-
firmed his voluntary participation and his intention to
comply with the protocol and the investigator’s instruc-
tions and to answer all questions under the study.
For any change in informed consent form (either due
to generation of new information or due to procedural
amendments) a prior permission from the IEC and ap-
proval from all investigators were considered mandatory.
Study protocol
After signing the informed consent document, subjects
were screened for demographic data, medical history,
clinical and physical examination including vital signs,
objective and subjective assessments. Total of 19 sub-
jects were enrolled in the study. As all the subjects had
ulcers within 48 h duration prior to screening visit, all
the subjects were enrolled on the screening visit, hence
screening visit (visit 1) and enrollment visit for all the
subjects were same.
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Treatment with AphtoFix® mouth ulcer cream was ini-
tiated immediately after enrolment. A small amount of
cream was collected on the tip of the finger by squeezing
and applied on affected area (mouth ulcers) using a
swiping action to ensure that it covers the whole area of
ulceration. The cream was applied multiple times during
the day (up to 4 applications per day) for maximum of
14 days, usually after meals and before going to sleep.
Application of cream was continued by the subjects
until reduction in ulcer size and symptoms. During the
enrollment visit (visit 2 day1), at each follow-up visit
(Visit 3 (day 4) and visit 4 (day 7)) and at the end of
study visit (visit 5), a clinical examination including vital
signs measurement as well as all subjective and objective
assessments were carried out. Subjects were evaluated
for physical examination at the time of complete healing
of ulcer. Adverse event evaluation was carried out at
Visit 3, Visit 4 and Visit 5 (day 14).
Efficacy assessment was done by evaluating the pri-
mary outcomes such as the mean of ulcer size reduction,
the change in number of ulcers and pain intensity reduc-
tion (VAS) assessed at Visit 3 (Day 4), Visit 4 (Day 7),
and Visit 5 (Day 14) and compared to baseline. The sec-
ondary outcomes are the evaluation of ulcer duration
(days needed for ulcer healing), the number and fre-
quency of application obtained from the subject diary
and finally the quality of life (QOL). The assessment of
QOL was evaluated by using a questionnaire subdivided
into 3 domains such as pain and functional level and fi-
nally medication and treatment limitation of subjects of
during treatment period (Additional file 1: Annex I).
Statistical analysis
All measurement variables were expressed as mean and
standard deviation whereas categorical variables were
expressed as percentage. Efficacy parameters were ana-
lyzed using the Wilcoxon matched-pairs signed rank test.
Reduction in pain and in number of ulcer from base-
line to each follow up visits (visit 3 and 4) and end of
study visit (visit 5) was analyzed using paired “t” test or
Wilcoxon test depending upon the distribution of data.
Normality test (Kolmogorov-Smirnov test or Shapiro-
Wilks test) was used to check the distribution of data.
P values less than 0.05 were considered as statisti-
cally significant difference. The data were presented
as mean ± Standard Deviation/Standard error mean
with 95 % confidence interval.
Results
In vitro biocompatibility safety assessment
No cytotoxic effect was observed on reconstructed gin-
gival tissues after 24 h of contact with AphtoFix®. The
viability was 95.81 % compared to the positive control
showing a viability equal to 1.85 %. In addition, the
product AphtoFix® was also not considered irritant.
Viability of the reconstructed human gingival tissues
after 2 h contact with AphtoFix®, followed by a 42 h re-
covery incubation was 92.55 % compared to the positive
control demonstrating a viability equal to 51.75 %.
Results are shown on Table 1.
In vivo safety assessment of AphtoFix® on healthy subjects
All of the 20 healthy subjects tolerated the product Aph-
toFix® mouth ulcer cream very well during the course of
the four-week test under dermatological and clinical ob-
servation. There were no undesired or even pathological
reactions. It can therefore be concluded that the use of
AphtoFix® mouth ulcer cream does not lead to any un-
desired skin or mucosa reactions.
In vivo clinical efficacy and safety assessment of AphtoFix®
on patients suffering from RAS
Primary end points
 Demographic characteristics of the study population
Nineteen patients were enrolled in the study (16
males; 03 females). The mean (± SD) age of study
subjects was 27.95 ± 7.75 years (range 18–46).
 Ulcer size reduction
Out of 19 subjects, 17 subjects were diagnosed with
a single ulcer and the remaining 2 subjects had 2
ulcers. All the subjects had ulcer sizes ranging from
4 mm to 7 mm. The gradual reduction in ulcer size
was measured after treatment at each post-
treatment visit. Significant gradual reduction in ulcer
size was observed at each post-treatment visit
compared with baseline. At visit 4, all mouth ulcers
were completely disappeared in 18 subjects. In the
remaining 1 subject, the ulcer disappeared at 13th
day. The difference of ulcer size between baseline
and visit 4 was statistically different: 4.33 ±
0.91 mm versus 0.25 ± 0.71 mm, p < 0.05).
Since no other medication that could impact mouth
ulcer evolution was allowed during the study, the
observed efficacy is solely related only to AphtoFix®
mouth ulcer cream application. Mean change in
ulcer size is showed in Table 2.
 Number of ulcers healed
A total 21 of mouth ulcers (2 subjects were having 2
ulcer sites) were observed in 19 subjects. Subjects
were also instructed to note if the ulcer had healed






Cytotoxicity (Viability) 100 % 1.85 % 95.81 %
Irritation (Viability) 100 % 51.75 % 92.55 %
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completely before scheduled visit in subject diary,
and to report this immediately to the hospital site
before the scheduled visit. Out of 21 mouth ulcers,
38.10 % (n = 8) ulcers were healed after 3 days of
treatment, 23.81 % (n = 5) ulcers were healed after
4 days of treatment, 14.29 % (n = 3) ulcers were
healed after 5 days of treatment, 19.05 % (n = 4)
ulcers were healed after 6 days and 4.76 % (n = 1)
ulcers were healed after 13 days of treatment
(Table 3).
 Pain intensity Assessment by VAS (Visual Analogue
Scale)
A significant reduction in pain intensity score (VAS)
was observed compared to baseline (1.58 ± 2.24 and
0.29 ± 0.76 at visit 3 and visit 4 respectively versus
6.58 ± 0.90 at baseline). Percentage of pain intensity
improvement were observed at visit 3, visit 4 and
visit 5 as 76.00 %, 95.66 % and 100 %, respectively.
Percentage improvement in pain assessment is
illustrated in Table 3.
Secondary endpoints: Quality of Life (QOL)
 Pain and functional limitation assessment
Both information on pain intensity and functional
limitation level assessment were the first domain of
QOL questionnaire. Both gradual reduction in pain
as well as the level of functional limitation during
daily activity was reported at each visit. There was
significant reduction in pain and functional level
during daily activity at visit 3 (3.16 ± 4.41) and visit 4
(0.71 ± 1.89) as compared to baseline (14.95 ± 3.27).
The improvement in pain and functional activity
was significantly greater at visit: in fact, pain and
functional level were zero at visit 4 in 18 subjects
which coincides with complete ulcer healing.
Percentage improvement in pain and functional level
at visit 3, visit 4 and visit 5 were observed as
78.88 %, 95.22 % and 100 %, respectively.
 Medication and treatment level assessment
Medication and treatment level was the second
domain of QOL questionnaire. Since the scoring for
this domain could only be obtained after study
treatment, therefore scoring was started from visit 3.
The Quality of life (QOL) related to medical
treatment was statistically significant at visit 4
(0.29 ± 0.76) as compared to visit 3 (1.58 ± 2.19),
indicating early relief from mouth ulcer. The
medical treatment requirement was gradually
decreased from follow up visit 3 to study visit 4.
Percentage of improvement was observed at visit 4
(81.92 %) and visit 5 (100 %).
Discussion
Although several factors are suspected including genet-
ics, stress, nutritional deficiencies, diet, hormonal
changes, and immunological disorders, the cause of RAS
is unknown [27, 35, 36]. Due to the indeterminate eti-
ology of RAS, it is difficult to find a definitive cure and
current treatments aimed to ameliorate the symptoms.
Treatment for RAS is symptomatic; the goals are essen-
tially pain reduction, healing time, number and size of
the ulcer, and to increase disease-free periods [37].
Based on the results of several case studies where indi-
vidual patients reported RAS reduction and concomitant
pain relief, we decided to investigate the efficacy of
AphtoFix® as a possible candidate treatment because of
its known adhesive properties.
AphtoFix® was formulated using a variety of similar in-
gredients that can be found in denture adhesive creams
including PVP. One of the most important applications
of PVP, either used alone or in combination with other
polymers, is the coating or the encapsulation of tissues,
organs or implants. This is because PVP provides a film
that is permeable to water and solutes and, at the same
time, protects tissue or implant surfaces from insults or
other damages like those due to bacterial colonization.
Once in contact with the oral mucosa, AphtoFix® creates
a thin, elastic cushion on mucosa surface. In addition,
the cream acts as a protection against pressure sores and
irritation of the nearby gums.
In this study, the application of AphtoFix® mouth ulcer
cream demonstrated a clear efficacy in the treatment of
RAS, based on objective parameters including of size of
ulcer, number of healed ulcer, duration of ulcer, and pain
intensity. These findings showed almost a significant re-
duction of both pain intensity and ulcer size after 4 days
of treatment compared to baseline values. Normally,
Table 2 Ulcer size reduction
Study visits Day 1 Day 4 Day 7
Number of subjects (N) 19 19 19
Mean ulcer size 4.33 ± 0.91 1.19 ± 1.69* 0.25 ± 0.71*
Percentage improvement
in ulcer size
0.00 % 72.53 % 94.23 %
Values are expressed as Mean ± SD. *p<0.05 as compared to baseline. Data
were analyzed by Wilcoxon matched-pairs signed rank test
Table 3 Number of healed ulcer and pain intensity (VAS)
Treatment days Day 3 Day 4 Day 7 Day 13
Number of healed ulcer (Improvement percentage) 8 (38.10 %) 5 (23.81 %) 4 (19.05 %) 1 (4.76 %)
Mean Pain intensity in (VAS) 6.58 ± 0.90 1.58 ± 2.24* 0.29 ± 0.76* 00
Values are expressed as Mean ± SD. * p<0.05 as compared to baseline. Data were analyzed by Wilcoxon matched-pairs signed rank test
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these ulcers are self-limiting and resolve within 7–10
days [1, 12, 14–16].
Several studies investigated the effects of some treatments
on pain and healing times. The results showed a significant
(p < 0.05) reduction in pain and healing time when
Aphtheal was applied to the ulcer 4 times a day from ulcer
onset until healing [38–40]. The study of Fontes et al.
showed that colchicine improved the symptoms of RAS
(pain and size) in 63 % of cases [41]. Symptoms of aphthous
ulcer were improved after the application of Pentoxifylline
and the response rates varied between 36 % and 63 % this
were rapidly followed by recurrences as soon as the medi-
cation was stopped [42, 43]. Steroids are usually used for a
short period (up to 1 month). Efficacy rate is reported be-
tween 30 % and 50 % [34]. Porter et al. showed that
HybenX application reduced the painful symptoms of RAS
[44]. Moghadamnia et al. evaluated the efficacy of licorice
bioadhesive hydrogel patches for controlling the pain and
reducing the healing time of RAS. The study showed that
licorice bioadhesive can be effective in the reduction of the
pain and the sizes of the inflammatory halo [45]. In another
clinical trial using herbal options muco-bioadhesive con-
taining ginger officinale extract was indicated relieving pain
of RAS but had no efficacy on ulcer diameter, inflamed halo
and healing time when compared to a placebo [46].
RAS causes not only pain but could also decrease the
Quality of Life (QOL) by interfering with swallowing,
drinking, eating and even speaking [47, 48]. A standard-
ized questionnaire was included in our study. The ana-
lysis showed a significant improvement of QOL.
Conclusion
The present study findings demonstrated that the topical
application of AphtoFix® mouth ulcer cream could ef-
fectively reduce the ulcer size and alleviate pain. As no
adverse or serious adverse events were reported during
the entire study period of both human clinical trials,
AphtoFix® can be considered as a safe and efficient prod-
uct for the treatment of minor RAS.
Additional file
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